REFERENCES
2. Bajbouj K, Al-Ali A, Ramakrishnan RK, Saber-Ayad M, Hamid Q. Histone modification in NSCLC: molecular mechanisms and therapeutic targets. Int J Mol Sci. 2021;22:11701.
3. Moldovanu D, de Koning HJ, van der Aalst CM. Lung cancer screening and smoking cessation efforts. Transl Lung Cancer Res. 2021;10:1099-109.
4. Li Q, Wang T, Tang Y, et al. A novel prognostic signature based on smoking-associated genes for predicting prognosis and immune microenvironment in NSCLC smokers. Cancer Cell Int. 2024;24:171.
5. Zhang Y, Han CY, Duan FG, et al. p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR/PI3K/AKT signaling. Cancer Cell Int. 2019;19:188.
6. Lim TKH, Skoulidis F, Kerr KM, et al. KRAS G12C in advanced NSCLC: prevalence, co-mutations, and testing. Lung Cancer. 2023;184:107293.
7. Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2020;61:167-79.
8. Dong RF, Zhu ML, Liu MM, et al. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: from molecular mechanisms to clinical research. Pharmacol Res. 2021;167:105583.
9. Ramírez Moreno M, Bulgakova NA. The cross-talk between EGFR and E-Cadherin. Front Cell Dev Biol. 2021;9:828673.
10. He Q, Qu M, Bao H, et al. Multiple post-translational modifications ensure EGFR functionality: potential therapeutic targets to overcome its drug-resistance mutations. Cytokine Growth Factor Rev. 2023;70:41-53.
11. Zhang J, Vokes N, Li M, et al. Overcoming EGFR-TKI resistance by targeting the tumor microenvironment. Chin Med J Pulm Crit Care Med. 2024;2:151-61.
12. Zhang X, Maity TK, Ross KE, et al. Alterations in the global proteome and phosphoproteome in third generation EGFR TKI resistance reveal drug targets to circumvent resistance. Cancer Res. 2021;81:3051-66.
13. Huang KY, Kao SH, Wang WL, et al. Small molecule T315 promotes Casitas B-lineage lymphoma-dependent degradation of epidermal growth factor receptor via Y1045 autophosphorylation. Am J Respir Crit Care Med. 2016;193:753-66.
14. Wang C, Zhang Y, Chen W, Wang Y, Xing D. Epidermal growth factor receptor PROTACs as an effective strategy for cancer therapy: a review. Biochim Biophys Acta Rev Cancer. 2023;1878:188927.
15. Hong X, Hsieh MT, Tseng TY, et al. Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma. J Biol Chem. 2023;299:104814.
16. Zhang S, Chen Y, Li C, et al. MCAM interacts with integrin β1 to promote EGFR-TKI resistance in lung adenocarcinoma through the JAK3 signalling pathway. J Transl Med. 2025;23:831.
17. Tong J, Taylor P, Peterman SM, Prakash A, Moran MF. Epidermal growth factor receptor phosphorylation sites Ser991 and Tyr998 are implicated in the regulation of receptor endocytosis and phosphorylations at Ser1039 and Thr1041. Mol Cell Proteomics. 2009;8:2131-44.
18. Guo H, Wang J, Ren S, et al. Targeting EGFR-dependent tumors by disrupting an ARF6-mediated sorting system. Nat Commun. 2022;13:6004.
19. Shen CH, Chou CC, Lai TY, et al. ZNRF1 mediates epidermal growth factor receptor ubiquitination to control receptor lysosomal trafficking and degradation. Front Cell Dev Biol. 2021;9:642625.
20. Lam D, Arroyo B, Liberchuk AN, Wolfe AL. Effects of N361 glycosylation on epidermal growth factor receptor biological function. bioRxiv 2024;2024.07.12.603279.
21. Liu W, Fan LX, Zhou X, Sweeney WE Jr , Avner ED, Li X. HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells. PLoS One. 2012;7:e49418.
22. Switzer CH, Glynn SA, Cheng RY, et al. S-nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer. Mol Cancer Res. 2012;10:1203-15.
23. Gao YS, Hubbert CC, Yao TP. The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation. J Biol Chem. 2010;285:11219-26.
24. Runkle KB, Kharbanda A, Stypulkowski E, et al. Inhibition of DHHC20-mediated EGFR palmitoylation creates a dependence on EGFR signaling. Mol Cell. 2016;62:385-96.
25. Ali A, Levantini E, Teo JT, et al. Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer. EMBO Mol Med. 2018;10:e8313.
26. Bollu LR, Katreddy RR, Blessing AM, et al. Intracellular activation of EGFR by fatty acid synthase dependent palmitoylation. Oncotarget. 2015;6:34992-5003.
27. Sato K. Cellular functions regulated by phosphorylation of EGFR on Tyr845. Int J Mol Sci. 2013;14:10761-90.
28. Clift CL, Drake RR, Mehta A, Angel PM. Multiplexed imaging mass spectrometry of the extracellular matrix using serial enzyme digests from formalin-fixed paraffin-embedded tissue sections. Anal Bioanal Chem. 2021;413:2709-19.
29. Ardito F, Giuliani M, Perrone D, Troiano G, Lo Muzio L. The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review). Int J Mol Med. 2017;40:271-80.
30. Halder S, Basu S, Lall SP, Ganti AK, Batra SK, Seshacharyulu P. Targeting the EGFR signaling pathway in cancer therapy: what’s new in 2023? Expert Opin Ther Targets. 2023;27:305-24.
31. Kim CL, Lim SB, Kim K, Jeong HS, Mo JS. Phosphorylation analysis of the Hippo-YAP pathway using Phos-tag. J Proteomics. 2022;261:104582.
32. Singh V, Ram M, Kumar R, Prasad R, Roy BK, Singh KK. Phosphorylation: implications in cancer. Protein J. 2017;36:1-6.
33. Del Piccolo N, Hristova K. Quantifying the interaction between EGFR dimers and Grb2 in live cells. Biophys J. 2017;113:1353-64.
34. Shi H, Zhang T, Yi Y, Ma Y. Inhibition of the Ras-ERK pathway in mitotic COS7 cells is due to the inability of EGFR/Raf to transduce EGF signaling to downstream proteins. Oncol Rep. 2016;35:3593-9.
35. Wang D, Liu G, Meng Y, Chen H, Ye Z, Jing J. The configuration of GRB2 in protein interaction and signal transduction. Biomolecules. 2024;14:259.
36. Du Y, Karatekin F, Wang WK, Hong W, Boopathy GTK. Cracking the EGFR code: cancer biology, resistance mechanisms, and future therapeutic frontiers. Pharmacol Rev. 2025;77:100076.
37. Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers. 2017;9:52.
38. Sun Q, Jackson RA, Ng C, Guy GR, Sivaraman J. Additional serine/threonine phosphorylation reduces binding affinity but preserves interface topography of substrate proteins to the c-Cbl TKB domain. PLoS One. 2010;5:e12819.
39. Hartman Z, Zhao H, Agazie YM. HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling. Oncogene. 2013;32:4169-80.
40. Wang P, Zhou R, Zhou R, et al. Epidermal growth factor potentiates EGFR(Y992/1173)-mediated therapeutic response of triple negative breast cancer cells to cold atmospheric plasma-activated medium. Redox Biol. 2024;69:102976.
41. Iida M, Brand TM, Campbell DA, Li C, Wheeler DL. Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor. Oncogene. 2013;32:759-67.
42. Atwell B, Chalasani P, Schroeder J. Nuclear epidermal growth factor receptor as a therapeutic target. Explor Target Antitumor Ther. 2023;4:616-29.
43. An Z, Aksoy O, Zheng T, Fan QW, Weiss WA. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene. 2018;37:1561-75.
44. Pham L, Arroum T, Wan J, et al. Regulation of mitochondrial oxidative phosphorylation through tight control of cytochrome c oxidase in health and disease - Implications for ischemia/reperfusion injury, inflammatory diseases, diabetes, and cancer. Redox Biol. 2024;78:103426.
45. Kwak SM, Seo J, Hwang JT, et al. EGFR-c-Src-mediated HDAC3 phosphorylation exacerbates invasion of breast cancer cells. Cells. 2019;8:930.
46. Che TF, Lin CW, Wu YY, et al. Mitochondrial translocation of EGFR regulates mitochondria dynamics and promotes metastasis in NSCLC. Oncotarget. 2015;6:37349-66.
47. Font-Mateu J, Sanllehí P, Sot J, et al. A progesterone derivative linked to a stable phospholipid activates breast cancer cell response without leaving the cell membrane. Cell Mol Life Sci. 2024;81:98.
48. Daveri E, Adamo AM, Alfine E, Zhu W, Oteiza PI. Hexameric procyanidins inhibit colorectal cancer cell growth through both redox and non-redox regulation of the epidermal growth factor signaling pathway. Redox Biol. 2021;38:101830.
49. Kohale IN, Yu J, Zhuang Y, et al. Identification of Src family kinases as potential therapeutic targets for chemotherapy-resistant triple negative breast cancer. Cancers. 2022;14:4220.
50. Ma Y, Zhang F, Li J, Li J, Li Y. Diverse perspectives on proteomic posttranslational modifications to address EGFR-TKI resistance in non-small cell lung cancer. Front Cell Dev Biol. 2024;12:1436033.
51. Martellucci S, Clementi L, Sabetta S, Mattei V, Botta L, Angelucci A. Src family kinases as therapeutic targets in advanced solid tumors: what we have learned so far. Cancers. 2020;12:1448.
52. Zhou B, Wang Y, Zhang L, et al. The palmitoylation of AEG-1 dynamically modulates the progression of hepatocellular carcinoma. Theranostics. 2022;12:6898-914.
53. Zhu J, Cao X, Chen Z, et al. Inhibiting S-palmitoylation arrests metastasis by relocating Rap2b from plasma membrane in colorectal cancer. Cell Death Dis. 2024;15:675.
54. Zhou B, Hao Q, Liang Y, Kong E. Protein palmitoylation in cancer: molecular functions and therapeutic potential. Mol Oncol. 2023;17:3-26.
55. Ma Y, Yuan X, Wei A, et al. Enhancing Gpx1 palmitoylation to inhibit angiogenesis by targeting PPT1. Redox Biol. 2024;77:103376.
56. Lv K, Ren JG, Han X, Gui J, Gong C, Tong W. Depalmitoylation rewires FLT3-ITD signaling and exacerbates leukemia progression. Blood. 2021;138:2244-55.
57. Zhang Q, Du Z, Zhou W, et al. ZDHHC1 downregulates LIPG and inhibits colorectal cancer growth via IGF2BP1 Palmitoylation. Cancer Gene Ther. 2024;31:1427-37.
58. Jia Y, Yun CH, Park E, et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016;534:129-32.
59. Kharbanda A, Walter DM, Gudiel AA, Schek N, Feldser DM, Witze ES. Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis. Sci Signal. 2020;13:eaax2364.
60. Bollu LR, Ren J, Blessing AM, et al. Involvement of de novo synthesized palmitate and mitochondrial EGFR in EGF induced mitochondrial fusion of cancer cells. Cell Cycle. 2014;13:2415-30.
61. Wang TH, Wu CC, Huang KY, et al. Profiling of subcellular EGFR interactome reveals hnRNP A3 modulates nuclear EGFR localization. Oncogenesis. 2020;9:40.
62. Chaturvedi S, Pandya N, Sadhukhan S, Sonawane A. Identification of selective plant-derived natural carotenoid and flavonoids as the potential inhibitors of DHHC-mediated protein S-palmitoylation: an in silico study. J Biomol Struct Dyn. 2025;43:5110-23.
63. U.S. FOOD & DRUG Administration. Orlistat (marketed as Alli and Xenical) information. Available from: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/orlistat-marketed-alli-and-xenical-information. [Last accessed on 2 Mar 2026].
64. Shao G, Wang R, Sun A, et al. The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells. Mol Cancer. 2018;17:24.
65. Singh S, Yeat NY, Wang YT, et al. PTPN23 ubiquitination by WDR4 suppresses EGFR and c-MET degradation to define a lung cancer therapeutic target. Cell Death Dis. 2023;14:671.
66. Awan AB, Osman MJA, Khan OM. Ubiquitination enzymes in cancer, cancer immune evasion, and potential therapeutic opportunities. Cells. 2025;14:69.
67. Hong SY, Lu YC, Hsiao SH, et al. Stabilization of AURKA by the E3 ubiquitin ligase CBLC in lung adenocarcinoma. Oncogene. 2022;41:1907-17.
68. Fu L, Cui CP, Zhang X, Zhang L. The functions and regulation of Smurfs in cancers. Semin Cancer Biol. 2020;67:102-16.
69. Wang X, Zhang Y, Wu Y, Cheng H, Wang X. The role of E3 ubiquitin ligases and deubiquitinases in bladder cancer development and immunotherapy. Front Immunol. 2023;14:1202633.
70. Shen J, Liu G, Qi H, Xiang X, Shao J. JMJD5 inhibits lung cancer progression by facilitating EGFR proteasomal degradation. Cell Death Dis. 2023;14:657.
71. Song F, Zhou M, Wang B, et al. Weak binding to E3 ubiquitin ligase c-Cbl increases EGFRvA protein stability. FEBS Lett. 2016;590:1345-53.
72. Kim MS, Kim MS. Deubiquitination of epidermal growth factor receptor by ubiquitin-specific peptidase 54 enhances drug sensitivity to gefitinib in gefitinib-resistant non-small cell lung cancer cells. PLoS One. 2025;20:e0320668.
73. Kim Y, Shiba-Ishii A, Nakagawa T, et al. Stratifin regulates stabilization of receptor tyrosine kinases via interaction with ubiquitin-specific protease 8 in lung adenocarcinoma. Oncogene. 2018;37:5387-402.
74. Niño CA, Wollscheid N, Giangreco G, Maspero E, Polo S. USP25 regulates EGFR fate by modulating EGF-induced ubiquitylation dynamics. Biomolecules. 2020;10:1548.
75. Zhou J, Wu L, Li W, et al. Long noncoding RNA LINC01485 promotes tumor growth and migration via inhibiting EGFR ubiquitination and activating EGFR/Akt signaling in gastric cancer. Onco Targets Ther. 2020;13:8413-25.
76. Liu Y, Liu R, Dong J, et al. Targeted protein degradation via cellular trafficking of nanoparticles. Nat Nanotechnol. 2025;20:296-302.
77. Lin TY, Hsu HY, Sun WH, Wu TH, Tsao SM. Induction of Cbl-dependent epidermal growth factor receptor degradation in Ling Zhi-8 suppressed lung cancer. Int J Cancer. 2017;140:2596-607.
78. Sirisaengtaksin N, Gireud M, Yan Q, et al. UBE4B protein couples ubiquitination and sorting machineries to enable epidermal growth factor receptor (EGFR) degradation. J Biol Chem. 2014;289:3026-39.
79. Tabernero L, Woodman P. Dissecting the role of His domain protein tyrosine phosphatase/PTPN23 and ESCRTs in sorting activated epidermal growth factor receptor to the multivesicular body. Biochem Soc Trans. 2018;46:1037-46.
80. Tito C, Masciarelli S, Colotti G, Fazi F. EGF receptor in organ development, tissue homeostasis and regeneration. J Biomed Sci. 2025;32:24.
81. Jeong CH. Inhibition of ubiquitin-specific peptidase 8 suppresses growth of gefitinib-resistant non-small cell lung cancer cells by inducing apoptosis. J Cancer Prev. 2015;20:57-63.
84. Kaszuba K, Grzybek M, Orłowski A, et al. N-Glycosylation as determinant of epidermal growth factor receptor conformation in membranes. Proc Natl Acad Sci U S A. 2015;112:4334-9.
85. Yen HY, Liu YC, Chen NY, et al. Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition. Proc Natl Acad Sci U S A. 2015;112:6955-60.
86. Lindsey S, Langhans SA. Epidermal growth factor signaling in transformed cells. Int Rev Cell Mol Biol. 2015;314:1-41.
87. Liu YC, Yen HY, Chen CY, et al. Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. Proc Natl Acad Sci U S A. 2011;108:11332-7.
88. Ankenbauer KE, Rao TC, Mattheyses AL, Bellis SL. Sialylation of EGFR by ST6GAL1 induces receptor activation and modulates trafficking dynamics. J Biol Chem. 2023;299:105217.
89. He X, Haselhorst T, von Itzstein M, Kolarich D, Packer NH, Kermode AR. Influence of an ER-retention signal on the N-glycosylation of recombinant human α-L-iduronidase generated in seeds of Arabidopsis. Plant Mol Biol. 2012;79:157-69.
90. He M, Zhou X, Wang X. Glycosylation: mechanisms, biological functions and clinical implications. Signal Transduct Target Ther. 2024;9:194.
91. Taylor ES, Pol-Fachin L, Lins RD, Lower SK. Conformational stability of the epidermal growth factor (EGF) receptor as influenced by glycosylation, dimerization and EGF hormone binding. Proteins. 2017;85:561-70.
92. Wu L, Cheng Y, Geng D, et al. O-GlcNAcylation regulates epidermal growth factor receptor intracellular trafficking and signaling. Proc Natl Acad Sci U S A. 2022;119:e2107453119.
93. Xu S, Wang H, Zhu Y, et al. Stabilization of EREG via STT3B-mediated N-glycosylation is critical for PDL1 upregulation and immune evasion in head and neck squamous cell carcinoma. Int J Oral Sci. 2024;16:47.
94. Gc S, Tuy K, Rickenbacker L, et al. α2,6 sialylation mediated by ST6GAL1 promotes glioblastoma growth. JCI Insight. 2022;7:e158799.
95. U.S. FOOD & DRUG Administration. Drugs@FDA: FDA-approved drugs. Approval history for Cisplatin (NDA #018057). Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018057. [Last accessed on 2 Mar 2026].
96. Mehta KA, Patel KA, Kunnumakkara AB, Patel PS. Curbing the deregulation of glycosylation in tongue carcinoma cells with natural compounds. Anticancer Agents Med Chem. 2021;21:1717-23.
97. Manabe Y, Takebe T, Kasahara S, et al. Development of a FUT8 inhibitor with cellular inhibitory properties. Angew Chem Int Ed Engl. 2024;63:e202414682.
98. He W, Li Q, Li X. Acetyl-CoA regulates lipid metabolism and histone acetylation modification in cancer. Biochim Biophys Acta Rev Cancer. 2023;1878:188837.
99. Bahl S, Ling H, Acharige NPN, Santos-Barriopedro I, Pflum MKH, Seto E. EGFR phosphorylates HDAC1 to regulate its expression and anti-apoptotic function. Cell Death Dis. 2021;12:469.
100. Ramazi S, Zahiri J. Posttranslational modifications in proteins: resources, tools and prediction methods. Database. 2021;2021:baab012.
101. Song H, Li CW, Labaff AM, et al. Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors. Biochem Biophys Res Commun. 2011;404:68-73.
102. Varga JK, Diffley K, Welker Leng KR, Fierke CA, Schueler-Furman O. Structure-based prediction of HDAC6 substrates validated by enzymatic assay reveals determinants of promiscuity and detects new potential substrates. Sci Rep. 2022;12:1788.
103. Wang Z, Tang F, Hu P, et al. HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma. Oncol Rep. 2016;36:589-97.
104. Jo H, Shim K, Jeoung D. Targeting HDAC6 to overcome autophagy-promoted anti-cancer drug resistance. Int J Mol Sci. 2022;23:9592.
105. Wen Y, Ye S, Li Z, et al. HDAC6 inhibitor ACY-1215 enhances STAT1 acetylation to block PD-L1 for colorectal cancer immunotherapy. Cancer Immunol Immunother. 2024;73:7.
106. Caligiuri M, Williams GL, Castro J, et al. FT-6876, a potent and selective inhibitor of CBP/p300, is active in preclinical models of androgen receptor-positive breast cancer. Target Oncol. 2023;18:269-85.
107. Lin W, Shang JX, Li XY, Zhou XF, Zhao LQ. Nitric oxide regulates multiple signal pathways in plants via protein S-nitrosylation. Curr Issues Mol Biol. 2025;47:407.
108. Bignon E, Allega MF, Lucchetta M, Tiberti M, Papaleo E. Computational structural biology of S-nitrosylation of cancer targets. Front Oncol. 2018;8:272.
109. Murillo-Carretero M, Torroglosa A, Castro C, Villalobo A, Estrada C. S-nitrosylation of the epidermal growth factor receptor: a regulatory mechanism of receptor tyrosine kinase activity. Free Radic Biol Med. 2009;46:471-9.
110. Cho B, Shin M, Chang E, Son S, Shin I, Shim J. S-nitrosylation-triggered unfolded protein response maintains hematopoietic progenitors in Drosophila. Dev Cell. 2024;59:1075-90.e6.
111. Freedman BI, Wuerth JP, Cartwright K, et al. Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy (ACTION II). Control Clin Trials. 1999;20:493-510.
113. Li H, Evenson RJ, Chreifi G, Silverman RB, Poulos TL. Structural basis for isoform selective nitric oxide synthase inhibition by thiophene-2-carboximidamides. Biochemistry. 2018;57:6319-25.
114. Isaac I, Patel L, Tran N, et al. Reengineering endogenous targeting lipid nanoparticles (ENDO) for systemic delivery of mRNA to pancreas. Adv Mater. 2025;37:e2507657.
115. Bhuia MS, Chowdhury R, Hasan R, et al. Trans-ferulic acid antagonizes the anti-inflammatory activity of etoricoxib: possible interaction of COX-1 and NOS. Biotechnol Appl Biochem. 2025;72:1284-301.
116. Jones RB, Dorsett KA, Hjelmeland AB, Bellis SL. The ST6Gal-I sialyltransferase protects tumor cells against hypoxia by enhancing HIF-1α signaling. J Biol Chem. 2018;293:5659-67.
117. Jameson NM, Ma J, Benitez J, et al. Intron 1-mediated regulation of EGFR expression in EGFR-dependent malignancies is mediated by AP-1 and BET proteins. Mol Cancer Res. 2019;17:2208-20.
118. Waudby CA, Alvarez-Teijeiro S, Josue Ruiz E, et al. An intrinsic temporal order of c-JUN N-terminal phosphorylation regulates its activity by orchestrating co-factor recruitment. Nat Commun. 2022;13:6133.
119. Qi Z, Hu L, Zhang J, et al. PCSK9 (proprotein convertase subtilisin/kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36. Circulation. 2021;143:45-61.
120. Funakoshi-Tago M, Tago K, Sonoda Y, Tominaga S, Kasahara T. TRAF6 and C-SRC induce synergistic AP-1 activation via PI3-kinase-AKT-JNK pathway. Eur J Biochem. 2003;270:1257-68.
121. Mertins P, Mani DR, Ruggles KV, et al; NCI CPTAC. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016;534:55-62.
122. Nishida N, Mimori K, Mori M, Calin GA. EGFR gets in the way of microRNA biogenesis. Cell Res. 2013;23:1157-8.
123. Shen J, Xia W, Khotskaya YB, et al. EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature. 2013;497:383-7.
124. Jiang Y, Xu Y, Zhu C, et al. STAT3 palmitoylation initiates a positive feedback loop that promotes the malignancy of hepatocellular carcinoma cells in mice. Sci Signal. 2023;16:eadd2282.
125. Yin J, Seo Y, Rhim J, et al. Cross-talk between PARN and EGFR-STAT3 signaling facilitates self-renewal and proliferation of glioblastoma stem cells. Cancer Res. 2023;83:3693-709.
126. Xu X, Liu Q, Zhang C, et al. Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence. Cell Death Dis. 2019;10:282.
127. Liu Y, Tavana O, Gu W. p53 modifications: exquisite decorations of the powerful guardian. J Mol Cell Biol. 2019;11:564-77.
128. Andonegui-Elguera S, Silva-Román G, Peña-Martínez E, et al. The genomic landscape of corticotroph tumors: from silent adenomas to ACTH-secreting carcinomas. Int J Mol Sci. 2022;23:4861.
129. Ho TLF, Lee MY, Goh HC, et al. Domain-specific p53 mutants activate EGFR by distinct mechanisms exposing tissue-independent therapeutic vulnerabilities. Nat Commun. 2023;14:1726.
130. Kurcon T, Liu Z, Paradkar AV, et al. miRNA proxy approach reveals hidden functions of glycosylation. Proc Natl Acad Sci U S A. 2015;112:7327-32.
131. Ryazansky S, Akulenko N. Fraternity of old-timers: how ubiquitin regulates miRNA functions. Bioessays. 2023;45:e2200220.
132. Dunphy K, Dowling P, Bazou D, O’Gorman P. Current methods of post-translational modification analysis and their applications in blood cancers. Cancers. 2021;13:1930.
